(s)-2-hydroxy-6-((4-(2-(2-hydroxyethyl)nicotinoyl)morpholin-3-yl)methoxy)benzaldehyd for use in the treatment of sickle cell disease
AssigneeGlobal Blood Therapeutics, Inc.
InventorsAline BERGESCH BARTH, Kenneth Leslie DUCHIN, Eleanor Allen LISBON, Arthur Chi Hang LO, Eric Iredell Zimmerman
Life of this patent
Estimating the term…
Abstract
Provided herein are methods for treating sickle cell disease comprising administering Compound I, a modulator of CN hemoglobin, according to certain dosing regimens.
Claims35
A method for treating sickle cell disease in a subject in need thereof, comprising administering to the subject a first dose of Compound I of formula:
- or a pharmaceutically acceptable salt thereof, for eight or more days,
- followed thereafter by a second dose of Compound I, or a pharmaceutically acceptable salt thereof, wherein the administrations of the first dose and the second dose provide about 25% to about 60% hemoglobin occupancy by Compound I.
A method for treating sickle cell disease in a subject in need thereof, comprising administering to the subject a first dose of about 200 mg per day to about 1600 mg per day of Compound I of formula:
- or a pharmaceutically acceptable salt thereof, for eight or more days,
- followed thereafter by a second dose of about 25 mg per day to about 500 mg per day of Compound I, or a pharmaceutically acceptable salt thereof.
A method for treating sickle cell disease in a subject in need thereof, comprising administering to the subject a first dose of about 300 mg once daily (QD) of Compound I of formula:
- or a pharmaceutically acceptable salt thereof, for fourteen days,
- followed thereafter by a second dose of 200 mg once daily (QD) of Compound I, or a pharmaceutically acceptable salt thereof.
A compound for use in a method of treating sickle cell disease in a subject in need thereof, wherein the compound is Compound I of formula:
- or a pharmaceutically acceptable salt thereof, and wherein the method comprises administering to the subject a first dose of Compound I, or a pharmaceutically acceptable salt thereof, for eight or more days,
- followed thereafter by a second dose of Compound I, or a pharmaceutically acceptable salt thereof, wherein the administrations of the first dose and the second dose provide about 25% to about 60% hemoglobin occupancy by Compound I.
A compound for use in a method of treating sickle cell disease in a subject in need thereof, wherein the compound is Compound I of formula:
- or a pharmaceutically acceptable salt thereof, and wherein the method comprises administering to the subject a first dose of about 200 mg per day to about 1600 mg pe day of Compound I, or a pharmaceutically acceptable salt thereof, for eight or more days,
- followed thereafter by a second dose of about 25 mg per day to about 500 mg per day of Compound I, or a pharmaceutically acceptable salt thereof.
A compound for use in a method of treating sickle cell disease in a subject in need thereof, wherein the compound is Compound I of formula:
- or a pharmaceutically acceptable salt thereof, and wherein the method comprises administering to the subject a first dose of about 300 mg once daily (QD) of Compound I, or a pharmaceutically acceptable salt thereof, for fourteen days,
- followed thereafter by a second dose of 200 mg once daily (QD) of Compound I, or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.